|
A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer. |
|
|
Employment - Best Doctors, Inc |
|
Consulting or Advisory Role - Foundation Medicine; Gerson Lehrman Group; Guidepoint Global; Leap Therapeutics; Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Employment - Aduro Biotech; Arcus Biosciences; Bellicum Pharmaceuticals |
Stock and Other Ownership Interests - Arcus Biosciences |
|
|
Employment - Arcus Biosciences; Bellicum Pharmaceuticals; Genentech/Roche |
Stock and Other Ownership Interests - Arcus Biosciences; Celgene; Denali Therapeutics; Roche/Genentech |
Consulting or Advisory Role - Bellicum Pharmaceuticals |
|
|
No Relationships to Disclose |
|
Melissa Constance Paoloni |
Employment - Arcus Biosciences |
Stock and Other Ownership Interests - Arcus Biosciences |
Consulting or Advisory Role - Amgen; Janssen; Lilly |
|
|
Employment - Arcus Biosciences; Biomarin (I); Denali Therapeutics (I); Genentech/Roche |
Leadership - Arcus Biosciences |
Stock and Other Ownership Interests - Arcus Biosciences; Biomarin (I); Denali Therapeutics (I) |
Patents, Royalties, Other Intellectual Property - Patent on molecule for the treatment of biomarker-selected gastric and urothelial bladder cancer |
Travel, Accommodations, Expenses - Arcus Biosciences; Genentech/Roche |